All In Biotech

Drug Trial Radar · NCT07095855

A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB

A Multicenter, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R (Canocapavir) in Combination With Nucleos(t)Ide Analog(NAs) Compared With NAs Monotherapy in Patients With Chronic Hepatitis B Who Have Received NAs Monotherapy for at Least 12 Months

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,300 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,300

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Jan 2028

Study completion Jan 2030

Sponsor

Sponsor type
Industry
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA ≥ 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.

Conditions

  • Chronic Hepatitis B

Interventions

  • ZM-H1505R 100mgDrug

    ZM-H1505R(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks and Part B open-label extension period 144 weeks.

  • ZM-H1505R PlaceboOther

    ZM-H1505R Placebo(100mg,QD) will be used in Part A double-blind treatment period for 48 weeks.

  • NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatmentsCombination product

    All eligible subjects will be use NAs ("Entecavir"or"Tenofovir"or"Tenofovir alafenamide"or"TMF") treatments during the study for 148 weeks, including Part A and Part B. Subjects will continue to use the NAs as combination therapy before enrollment, the dosage will not be adjusted during the study. Subjects use in accordance with medical advice andinstructions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of subjects achieves complete virologic response (CVR) at week 48 of treatment.Time frame: 48 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Hospital of Jilin University

    Changchun, Jilin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.